| Identification | Back Directory | [Name]
C18 Dihydroceramide | [CAS]
2304-80-5 | [Synonyms]
C18 Dihydroceramide (d18:0/18:0)
N-[(1S,2R)-2-Hydroxy-1-(hydroxyMethyl)heptadecyl]octadecanaMide | [Molecular Formula]
C36H73NO3 | [MDL Number]
MFCD01076443 | [MOL File]
2304-80-5.mol | [Molecular Weight]
567.977 |
| Chemical Properties | Back Directory | [Appearance]
White Crystalline Solid | [Melting point ]
104-106°C | [Boiling point ]
694.8±45.0 °C(Predicted) | [density ]
0.909±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: Soluble; Ethanol: Warmed | [form ]
A crystalline solid | [pka]
14.30±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Chemical Properties]
White Crystalline Solid | [Uses]
C18 Dihydroceramide can be used for ceramide composition with repairing function and cosmetic. | [Definition]
ChEBI: N-octodecanoylsphinganine is a dihydroceramide in which the ceramide N-acyl group is specified as octadecanoyl (stearoyl). It has a role as a mouse metabolite. It is a N-acylsphinganine and a N-stearoyl-sphingoid base. It is functionally related to an octadecanoic acid. | [Biological Activity]
Dihydroceramides act as precursors for ceramides in the mammalian de-novo sphingolipid pathway. vitamin D supplementation increases plasma C18 dihydroceramide (C18-DHC) levels in type 2 diabetes mellitus (T2D) patients. Low serum concentration of C18-DHC has been observed in patients with history of graft rejection and ischemic type biliary lesions (ITBL). Thereforeit can be used as a predictor of graft rejection. |
|
| Company Name: |
Alfa Chemistry
|
| Tel: |
1-516-6625404 |
| Website: |
https://www.alfa-chemistry.com |
|